Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCO-48 Fumarate in Chronic HBV
NCT04629976Phase 1Completed
- Sponsor
- Nucorion Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Sep 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NUC-1010 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Nucorion Pharmaceuticals. Primary endpoint: Change in hepatitis B virus (HBV) DNA at Week 4. Started Jan 2021; status: completed.
02
Drugs
NUC-1010
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04629976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629976.